# Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

> **NCT06413342** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 191 (estimated)

## Conditions studied

- Esophageal Cancer
- Chemoradiotherapy
- Sintilimab
- Immunotherapy
- Elderly Patients

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06413342
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 191 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413342, "Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06413342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*